REFERENCES
1. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109-16.
2. Foxtrot Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol 2012;13:1152-60.
3. Jakobsen A, Andersen F, Fischer A, Jensen LH, Jorgensen JC, et al. Neoadjuvant chemotherapy in locally advanced colon cancer. A phase II trial. Acta Oncol 2015;54:1747-53.
5. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011;10:417-27.
6. Sun Y, Bai Y, Zhang F, Wang Y, Guo Y, et al. miR-126 inhibits non-small cell lung cancer cells proliferation by targeting EGFL7. Biochem Biophys Res Commun 2010;391:1483-9.
7. Saito Y, Friedman JM, Chihara Y, Egger G, Chuang JC, et al. Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Biochem Biophys Res Commun 2009;379:726-31.
8. Hu MH, Ma CY, Wang XM, Ye CD, Zhang GX, et al. MicroRNA-126 inhibits tumor proliferation and angiogenesis of hepatocellular carcinoma by down-regulating EGFL7 expression. Oncotarget 2016;7:66922-34.
9. Gong C, Fang J, Li G, Liu HH, Liu ZS. Effects of microRNA-126 on cell proliferation, apoptosis and tumor angiogenesis via the down-regulating ERK signaling pathway by targeting EGFL7 in hepatocellular carcinoma. Oncotarget 2017;8:52527-42.
10. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 2008;15:272-84.
11. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008;15:261-71.
12. Parker LH, Schmidt M, Jin SW, Gray AM, Beis D, et al. The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation. Nature 2004;428:754-8.
13. Nikolic I, Stankovic ND, Bicker F, Meister J, Braun H, et al. EGFL7 ligates alphavbeta3 integrin to enhance vessel formation. Blood 2013;121:3041-50.
14. Hansen TF, Soerensen FB, Lindebjerg J, Jakobsen A. The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer. BMC Cancer 2012;12:83.
15. Hansen TF, Nielsen BS, Sorensen FB, Johnsson A, Jakobsen A. Epidermal growth factor-like domain 7 predicts response to first-line chemotherapy and bevacizumab in patients with metastatic colorectal cancer. Mol Cancer Ther 2014;13:2238-45.
16. Hansen TF, Kjaer-Frifeldt S, Morgenthaler S, Blondal T, Lindebjerg J, et al. The prognostic value of microRNA-126 and microvessel density in patients with stage II colon cancer: results from a population cohort. J Transl Med 2014;12:254.
17. Hansen TF, Nielsen BS, Jakobsen A, Sorensen FB. Intra-tumoural vessel area estimated by expression of epidermal growth factor-like domain 7 and microRNA-126 in primary tumours and metastases of patients with colorectal cancer: a descriptive study. J Transl Med 2015;13:10.
18. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005;93:387-91.
19. Hansen TF, Carlsen AL, Heegaard NH, Sorensen FB, Jakobsen A. Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer. Br J Cancer 2015;112:624-9.
20. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008;3:1101-8.
21. Li XM, Wang AM, Zhang J, Yi H. Down-regulation of miR-126 expression in colorectal cancer and its clinical significance. Med Oncol 2011;28:1054-7.
22. Li N, Tang A, Huang S, Li Z, Li X, et al. MiR-126 suppresses colon cancer cell proliferation and invasion via inhibiting RhoA/ROCK signaling pathway. Mol Cell Biochem 2013;380:107-19.
23. Ebrahimi F, Gopalan V, Wahab R, Lu CT, Smith RA, et al. Deregulation of miR-126 expression in colorectal cancer pathogenesis and its clinical significance. Exp Cell Res 2015;339:333-41.
24. Liu Y, Zhou Y, Feng X, Yang P, Yang J, et al. Low expression of microRNA-126 is associated with poor prognosis in colorectal cancer. Genes Chromosomes Cancer 2014;53:358-65.
25. Jorgensen S, Baker A, Moller S, Nielsen BS. Robust one-day in situ hybridization protocol for detection of microRNAs in paraffin samples using LNA probes. Methods 2010;52:375-81.
26. Nielsen BS, Jorgensen S, Fog JU, Solkilde R, Christensen IJ, et al. High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patietns. Clin Exp Metastasis 2011;28:27-38.
27. Guo C, Sah JF, Beard L, Wilson JK, Markowitz SD, et al. The noncoding RNA, miR- 126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosomes Cancer 2008;47:939-46.
28. Zhu N, Zhang D, Xie H, Zhou Z, Chen H, et al. Endothelial-specific intron-derived miR-126 is down-regulated in human breast cancer and targets both VEGF-A and PIK3R2. Mol Cell Biochem 2011;351:157-64.
29. Liu Y, Zhou Y, Feng X, An P, Quan X, et al. MicroRNA-126 functions as a tumor suppressor in colorectal cancer cells by targeting CXCR4 via the AKT and ERK1/2 signalling pathways. Int J Oncol 2014;44:203-10.
30. Zhou Y, Feng X, Liu YL, Ye SC, Wang H, et al. Down-regulation of miR-126 is associated with colorectal cancer cells proliferation, migration and invasion by targeting IRS-1 via the AKT and ERK1/2 signalling pathways. PLoS One 2013;8:e81203.
31. Hara T, Jones MF, Subramanian M, Li XL, Ou O, et al. Selective targeting of KRAS-mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-mutant cells. Oncotarget 2014;5:7635-50.
32. Dong Y, Fu C, Guan H, Zhang Z, Zhou T, et al. Prognostic significance of miR-126 in various cancers: a meta-analysis. Onco Targets Ther 2016;9:2547-55.
33. Yan J, Ma S, Zhang Y, Yin C, Zhou X, et al. Potential role of mircroRNA-126 in the diagnosis of cancers. A systematic review and meta-analysis. Medicine 2016;95:e4644.
